Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (73)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Catchpole, C. R.
Right arrow Articles by Wise, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Catchpole, C. R.
Right arrow Articles by Wise, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 39, 255-260, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy

JOURNAL ARTICLE

A reassessment of the in-vitro activity of colistin sulphomethate sodium

CR Catchpole, JM Andrews, N Brenwald and R Wise
Department of Microbiology, City Hospital NHS Trust, Birmingham, UK.

The in-vitro activity of colistin sulphomethate sodium was compared with that of other commonly used antimicrobial agents against 377 recent clinical isolates of Gram-negative bacteria (including 94 strains of Pseudomonas aeruginosa from patients with cystic fibrosis) and 16 organisms with defined resistance patterns. Colistin was active against most strains of P. aeruginosa (MIC90 4 mg/L), Shigella spp. (MIC90 0.5 mg/L), Salmonella spp. (MIC90 1 mg/L), Acinetobacter spp. (MIC90 2 mg/L), Citrobacter spp. (MIC90 1 mg/L), Escherichia coli (MIC90 1 mg/L), Klebsiella spp. (MIC90 8 mg/L) and Enterobacter spp. (MIC50 1 mg/L). No useful activity was demonstrated against Providentia spp. or Serratia spp. The results show that colistin remains a useful antimicrobial agent against Gram-negative bacteria, particularly those strains which are resistant to more commonly used antibiotics.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. Walkty, M. DeCorby, K. Nichol, J. A. Karlowsky, D. J. Hoban, and G. G. Zhanel
In Vitro Activity of Colistin (Polymyxin E) against 3,480 Isolates of Gram-Negative Bacilli Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007-2008
Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4924 - 4926.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. Aoki, K. Tateda, Y. Kikuchi, S. Kimura, C. Miyazaki, Y. Ishii, Y. Tanabe, F. Gejyo, and K. Yamaguchi
Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa
J. Antimicrob. Chemother., March 1, 2009; 63(3): 534 - 542.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
V. Savini, C. Catavitello, M. Talia, A. Balbinot, F. Febbo, A. Pompilio, G. Di Bonaventura, R. Piccolomini, and D. D'Antonio
Isolation of colistin-resistant Hafnia alvei
J. Med. Microbiol., February 1, 2009; 58(2): 278 - 280.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
D. Landman, C. Georgescu, D. A. Martin, and J. Quale
Polymyxins Revisited
Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. Y. Peleg, H. Seifert, and D. L. Paterson
Acinetobacter baumannii: Emergence of a Successful Pathogen
Clin. Microbiol. Rev., July 1, 2008; 21(3): 538 - 582.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. P. Zavascki, L. Z. Goldani, J. Li, and R. L. Nation
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1206 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Quinteira, F. Grosso, H. Ramos, and L. Peixe
Molecular Epidemiology of Imipenem-Resistant Acinetobacter haemolyticus and Acinetobacter baumannii Isolates Carrying Plasmid-Mediated OXA-40 from a Portuguese Hospital
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3465 - 3466.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
F. G. Rios, C. M. Luna, B. Maskin, A. Saenz. Valiente, M. Lloria, S. Gando, C. Sosa, S. Baquero, C. Llerena, C. Petrati, et al.
Ventilator-associated pneumonia due to colistin susceptible-only microorganisms
Eur. Respir. J., August 1, 2007; 30(2): 307 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
T. M. Arnold, G. N. Forrest, and K. J. Messmer
Polymyxin antibiotics for gram-negative infections
Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 819 - 826.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
H. A Hakeam and A. M Almohaizeie
Hypotension Following Treatment with Aerosolized Colistin in a Patient with Multidrug-Resistant Pseudomonas aeruginosa
Ann. Pharmacother., September 1, 2006; 40(9): 1677 - 1680.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. H. Scheetz, K. M. Hurt, G. A. Noskin, and C. M. Oliphant
Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens.
Am. J. Health Syst. Pharm., July 15, 2006; 63(14): 1346 - 1360.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Koeman, A. J. A. M. van der Ven, E. Hak, H. C. A. Joore, K. Kaasjager, A. G. A. de Smet, G. Ramsay, T. P. J. Dormans, L. P. H. J. Aarts, E. E. de Bel, et al.
Oral Decontamination with Chlorhexidine Reduces the Incidence of Ventilator-associated Pneumonia
Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1348 - 1355.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. J. Bergen, J. Li, C. R. Rayner, and R. L. Nation
Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1953 - 1958.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
F. Ratjen, E. Rietschel, D. Kasel, R. Schwiertz, K. Starke, H. Beier, S. van Koningsbruggen, and H. Grasemann
Pharmacokinetics of inhaled colistin in patients with cystic fibrosis
J. Antimicrob. Chemother., February 1, 2006; 57(2): 306 - 311.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. L Quinn, J. P Parada, J. Belmares, and J P. O'Keefe
Intrathecal Colistin and Sterilization of Resistant Pseudomonas aeruginosa Shunt Infection
Ann. Pharmacother., May 1, 2005; 39(5): 949 - 952.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
L. A. Arroyo, A. Garcia-Curiel, M. E. Pachon-Ibanez, A. C. Llanos, M. Ruiz, J. Pachon, and J. Aznar
Reliability of the E-Test Method for Detection of Colistin Resistance in Clinical Isolates of Acinetobacter baumannii
J. Clin. Microbiol., February 1, 2005; 43(2): 903 - 905.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. A. Alothman, B. Ho, M. M. Alsaadi, S. L. Ho, L. O'Drowsky, E. Louca, and A. L. Coates
Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis
Chest, February 1, 2005; 127(2): 522 - 529.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
D. Berlana, J. M. Llop, E. Fort, M. B. Badia, and R. Jodar
Use of colistin in the treatment of multiple-drug-resistant gram-negative infections
Am. J. Health Syst. Pharm., January 1, 2005; 62(1): 39 - 47.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Montero, J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Borraz, and F. Gudiol
Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model
J. Antimicrob. Chemother., December 1, 2004; 54(6): 1085 - 1091.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Li, K. Coulthard, R. Milne, R. L. Nation, S. Conway, D. Peckham, C. Etherington, and J. Turnidge
Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis
J. Antimicrob. Chemother., December 1, 2003; 52(6): 987 - 992.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
D. Torrallardona, M. R. Conde, I. Badiola, J. Polo, and J. Brufau
Effect of fishmeal replacement with spray-dried animal plasma and colistin on intestinal structure, intestinal microbiology, and performance of weanling pigs challenged with Escherichia coli K99
J Anim Sci, May 1, 2003; 81(5): 1220 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
B. W. Gunderson, K. H. Ibrahim, L. B. Hovde, T. L. Fromm, M. D. Reed, and J. C. Rotschafer
Synergistic Activity of Colistin and Ceftazidime against Multiantibiotic-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model
Antimicrob. Agents Chemother., March 1, 2003; 47(3): 905 - 909.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Montero, J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Ardanuy, and F. Gudiol
Efficacy of Colistin versus {beta}-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii
Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1946 - 1952.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T. Schulin
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany
J. Antimicrob. Chemother., February 1, 2002; 49(2): 403 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. H. Yau, B. Ho, N. S. Tan, M. L. Ng, and J. L. Ding
High Therapeutic Index of Factor C Sushi Peptides: Potent Antimicrobials against Pseudomonas aeruginosa
Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2820 - 2825.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
J. Li, J. Turnidge, R. Milne, R. L. Nation, and K. Coulthard
In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis
Antimicrob. Agents Chemother., March 1, 2001; 45(3): 781 - 785.
[Abstract] [Full Text]

Home page
 J. Clin. Microbiol.Home page
A. C. Gales, A. O. Reis, and R. N. Jones
Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines
J. Clin. Microbiol., January 1, 2001; 39(1): 183 - 190.
[Abstract] [Full Text]

Home page
 ChestHome page
S. L. Katz, S. L. Ho, and A. L. Coates
Nebulizer Choice for Inhaled Colistin Treatment in Cystic Fibrosis
Chest, January 1, 2001; 119(1): 250 - 255.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
X. Corbella, A. Montero, M. Pujol, M. A. Domínguez, J. Ayats, M. J. Argerich, F. Garrigosa, J. Ariza, and F. Gudiol
Emergence and Rapid Spread of Carbapenem Resistance during a Large and Sustained Hospital Outbreak of Multiresistant Acinetobacter baumannii
J. Clin. Microbiol., November 1, 2000; 38(11): 4086 - 4095.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. H. HAMER
Treatment of Nosocomial Pneumonia and Tracheobronchitis Caused by Multidrug-Resistant Pseudomonas aeruginosa with Aerosolized Colistin
Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 328 - 330.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.